



29 April 2021

Tender results

PHARMAC has resolved to award tenders for Principal Supply Status for some products included in the 2020/21 Invitation to Tender, dated 2 November 2020 and has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2019/20 Invitation to Tender dated 1 November 2019.

Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status, Sole Subsidised Supply, or Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:

- For new listings, by 4pm on the 12th of May 2021 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change

PHARMAC cannot list a product (and pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – https://pharmac.govt.nz/medicine-funding-and-supply/make-an-application/pharmaconnect-make-a-medicine-funding-application/process-for-notification-of-product-changes/

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (http://www.pgnz.org.nz/about-us-1/pharmacode) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (http://www.nzulm.org.nz/sponsors). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to

A1487576 Page 1 of 8



the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

A1487576 Page 2 of 8



2020/21 Tender - Principal Supply Status applies until 30 June 2024

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date
Diclofenac sodium	Eye drops 0.1%; 5 ml OP dropper bottle	\$13.80	\$8.80	Voltaren Ophtha (Novartis)	1 June 2021	1 November 2021
Dorzolamide with timolol	Eye drops 2% with timolol 0.5%; 5 ml OP dropper bottle	\$2.87	\$2.73	Dortimopt (Mylan)	1 July 2021	1 December 2021
Filgrastim	Inj 300 mcg per 0.5 ml prefilled syringe; 10 prefilled syringe pack	\$96.22	\$96.22	Nivestim (Pfizer)	1 July 2021	1 December 2021
Filgrastim	Inj 480 mcg per 0.5 ml prefilled syringe; 10 prefilled syringe pack	\$161.50	\$148.58	Nivestim (Pfizer)	1 July 2021	1 December 2021
Ornidazole	Tab 500 mg, 10 tablet blister pack	\$32.95	\$36.16	Arrow-Ornidazole (Teva)	1 July 2021	1 December 2021

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date	Brand (Supplier) affected by delisting)
Bisacodyl	Tab 5 mg; 200 tablet blister pack	\$5.99	\$5.80	Pharmacy Health (PSM Healthcare)	1 November 2021	1 April 2022	Lax-Tab (AFT)
Lopinavir with ritonavir	Tab 100 mg with ritonavir 25 mg; 60 tablet blister pack	\$183.75	\$150.00	Lopinavir/Ritonavir Mylan (Mylan)	1 September 2021	1 February 2022	Kaletra (AbbVie)

A1487576 Page 3 of 8



Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date	Brand (Supplier) affected by delisting)
Lopinavir with ritonavir	Tab 200 mg with ritonavir 50 mg; 120 tablet blister pack	\$463.00	\$295.00	Lopinavir/Ritonavir Mylan (Mylan)	1 September 2021	1 February 2022	Kaletra (AbbVie)
Rivastigmine	Patch 4.6 mg per 24 hour; 30 patch pack	\$48.75	\$38.00	Rivastigmine Patch BNM 5 (Boucher and Muir)	1 September 2021	1 February 2022	Generic Partners (Generic Partners)
Rivastigmine	Patch 9.5 mg per 24 hours; 30 patch pack	\$48.75	\$38.00	Rivastigmine Patch BNM 10 (Boucher and Muir)	1 September 2021	1 February 2022	Generic Partners (Generic Partners)
Varenicline tartrate	Tab 0.5 mg x 11 and 1 mg x 42; 53 tablet blister pack	\$25.64	\$16.67	Varenicline Pfizer (Pfizer)	1 August 2021	1 January 2022	Champix (Pfizer) ¹
Varenicline tartrate	Tab 1 mg; 56 tablet blister pack	\$27.10	\$17.62	Varenicline Pfizer (Pfizer)	1 August 2021	1 January 2022	Champix (Pfizer) ¹
¹ Champix will be temporari	ly listed from 1 May 2021.	•	•	<u> </u>	•		

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply Status date
Diclofenac sodium	Eye drops 0.1%; 5 ml dropper bottle	\$13.80	\$8.80	Voltaren Ophtha (Novartis)	5%	1 June 2021	1 November 2021
Dorzolamide with timolol	Eye drops 2% with timolol 0.5%, 5 ml dropper bottle	\$2.87	\$2.73	Dortimopt (Mylan)	5%	1 July 2021	1 December 2021
Filgrastim	Inj 300 mcg per 0.5 ml prefilled syringe; 10 prefilled syringe pack	\$96.22	\$96.22	Nivestim (Pfizer)	5%	1 July 2021	1 December 2021

A1487576 Page 4 of 8



Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply Status date
Filgrastim	Inj 480 mcg per 0.5 ml prefilled syringe; 10 prefilled syringe pack	\$161.50	\$148.58	Nivestim (Pfizer)	5%	1 July 2021	1 December 2021
Ornidazole	Tab 500 mg, 10 tablet blister pack	\$32.95	\$36.16	Arrow-Ornidazole (Teva)	5%	1 July 2021	1 December 2021

4. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply Status date	Brand (Supplier) affected by delisting
Bisacodyl	Tab 5 mg; 200 tablet blister pack	\$5.99	\$5.80	Pharmacy Health (PSM Healthcare)	5%	1 November 2021	1 April 2022	Lax-Tab (AFT)
Lopinavir with ritonavir	Tab 100 mg with ritonavir 25 mg; 60 tablet blister pack	\$183.75	\$150.00	Lopinavir/Ritonavir Mylan (Mylan)	5%	1 September 2021	1 February 2022	Kaletra (AbbVie)
Lopinavir with ritonavir	Tab 200 mg with ritonavir 50 mg; 120 tablet blister pack	\$463.00	\$295.00	Lopinavir/Ritonavir Mylan (Mylan)	5%	1 September 2021	1 February 2022	Kaletra (AbbVie)
Rivastigmine	Patch 4.6 mg per 24 hour; 30 patch pack	\$48.75	\$38.00	Rivastigmine Patch BNM 5 (Boucher and Muir)	5%	1 September 2021	1 February 2022	Generic Partners (Generic Partners)
Rivastigmine	Patch 9.5 mg per 24 hours; 30 patch pack	\$48.75	\$38.00	Rivastigmine Patch BNM 10 (Boucher and Muir)	5%	1 September 2021	1 February 2022	Generic Partners (Generic Partners)

A1487576 Page 5 of 8



2019/20 Tender - Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2023

Community pharmaceutical tenders - Section B of the Pharmaceutical Schedule

5. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	New pack price	Sole supply brand (Supplier)	Listing date	Sole Subsidised Supply date		
Tacrolimus ² Oint 0.1%, 30 g OP tube \$33.00 Zematop (Douglas)		1 October 2021	1 March 2022				
² Special Authority criteria will apply as consulted on <u>11 August 2020</u> .							

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

6. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Tacrolimus ³	Oint 0.1%, 30 g tube	\$33.00	Zematop (Douglas)	1%	1 October 2021	1 March 2022
³ Hospital restriction criteria will apply as consulted on <u>11 August 2020.</u>						

A1487576 Page 6 of 8



Tender declines - Products where no tender is to be awarded for Principal Supply Status, Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Principal Supply Status, Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

- the 2020/21 Invitation to Tender, dated 2 November 2020
- the 2019/20 Invitation to Tender, dated 1 November 2019
- the 2018/19 Invitation to Tender, dated 1 November 2018

2020/21 Invitation to Tender

Chemical name	Line item
Atovaquone with proguanil hydrochloride	Tab 62.5 mg with proguanil hydrochloride 25 mg
Atovaquone with proguanil hydrochloride	Tab 250 mg with proguanil hydrochloride 100 mg
Budesonide	Rectal enema 2 – 4 mg
Calcium carbonate	Orai liq
Calcium carbonate	Tab eff 0.875 – 175 g (0.5 g – 1 g elemental)
Calcium gluconate	Gel 2.5%
Captopril	Oral liq 5 mg per ml
Crotamiton	Lotn 10%
Dantrolene sodium	Cap 25 mg
Dantrolene sodium	Cap 50 mg
Dantrolene sodium	Inj
Fexofenadine hydrochloride	Tab 60 mg
Fexofenadine hydrochloride	Tab 120 mg
Fexofenadine hydrochloride	Tab 180 mg
Glyceryl trinitrate	Inj 1 mg per ml, 5 ml

Chemical name	Line item
Glyceryl trinitrate	Inj 1 mg per ml, 50 ml
Linezolid	Oral liq 20 mg per ml
Methylprednisolone	Tab 4 mg
Methylprednisolone	Tab 100 mg
Methylprednisolone aceponate	Crm 0.1%
Methylprednisolone acetate	Inj 40 mg per ml, 1 ml
Methylprednisolone sodium	Inj 40 mg
Methylprednisolone sodium	Inj 125 mg
Methylprednisolone sodium	Inj 500 mg
Methylprednisolone sodium	Inj 1 g
Metoprolol tartrate	Tab long-acting 200 mg
Promethazine hydrochloride	Inj 25 mg per ml, 2 ml
Ticarcillin with clavulanic acid	Inj 3 g with clavulanic acid 0.1 mg
Tropisetron	Inj 1 mg per ml, 2 ml
Tropisetron	Inj 1 mg per ml, 5 ml

A1487576 Page 7 of 8



2019/20 Invitation to Tender

Chemical name	Line item
Clotrimazole	Crm 1%
Irbesartan	Tab/cap 75 mg
Irbesartan	Tab/cap 150 mg
Irbesartan	Tab/cap 300 mg
Irbesartan with hydrochlorothiazide	Tab/cap 150 mg with hydrochlorothiazide 12.5 mg
Irbesartan with hydrochlorothiazide	Tab/cap 300 mg with hydrochlorothiazide 12.5 mg
Irbesartan with hydrochlorothiazide	Tab/cap 300 mg with hydrochlorothiazide 25 mg
Sodium alginate with sodium bicarbonate and calcium carbonate	Oral liq
Tadalafil	Tab/cap 2.5 mg
Tadalafil	Tab/cap 5 mg
Tadalafil	Tab/cap 10 mg
Tadalafil	Tab/cap 20 mg

2018/19 Invitation to Tender

Chemical name	Line item
Cefalexin	Cap 500 mg
Tenoxicam	Inj 20 mg

For products included in the 2018/19, 2019/20 and 2020/21 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made. If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.

A1487576 Page 8 of 8